Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A southwest oncology group study

Journal of Immunotherapy

Volumn 21, Issue 6, 1998, Pages 440-446

  Whitehead, Robert P ^a   Unger, Joseph M ^b   Wendall Goodwin, J ^c   Walker, Michael J ^d   Thompson, John A ^e   Flaherty, Lawrence E ^f   Sondak, Vernon K ^g  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Ozarks Regional CCOP   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Disseminated malignant melanoma; Phase II trial; Recombinant human IL 4

Indexed keywords

ATROPINE; COCODAMOL; DIPHENOXYLATE; LORAZEPAM; PARACETAMOL; PROCHLORPERAZINE; RECOMBINANT INTERLEUKIN 4; SUCRALFATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER INHIBITION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOMODULATION; MALAISE; MALE; MELANOMA; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; VOMITING;

EID: 0031786674     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199811000-00006     Document Type: Article

References (26)

1. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: De Vita Jr V, Heilman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott, 1993: 1612-61.
2. Parker SI, Tong T, Bolden S, Wingo PA. Cancer Statistics 1996. Ca 65:5-27, 1996.
3. Martinez OM, Gibbons RS, Garovoy MR, Aronson FR. IL-4 in hibits IL-2 receptor expression and IL-2 dependent proliferation of human T-cells. J Immunol 1990;144:2211-2215.
4. Higuchi CM, Thompson JA, Lindgren CG, et al. Induction of lymphokine activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 1989;49:6487-92.
5. Treisman J, Higuchi CM, Thompson JA, et al. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients. Cancer Res 1990;50:1160-4.
6. Spits H, Yssel H, Takebe Y, et al. Recombinant interleukin 4 promotes the growth of human T cells. J Immunol 1987; 139: 1142-7.
7. Widmer MB, Acres RB, Sassenfeld HM, Grabstein KH. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med 1987; 166: 1447-55.
8. Mossman RT, Zlotnik A. Multiple functions of interleukin 4 and its role in immune regulation. In: Habenicht A, ed. Growth factors differentiation factors and cytokines. Berlin: Springer-Verlag, 1990:129-46.
9. Vercelli D, Jabara HH, Lee BW, Woodland N, Geha RS, Leung DYM. Human recombinant interleukin 4 induces FceR2/CD23 on normal human monocytes. J Exp Med 1988;167:1406-16.
10. Defrance T, Aubry JP, Rousset F, et al. Human recombinant interleukin 4 induces Fee receptors (CD23) on normal human B lymphocytes. J Exp Med 1987;165:1459-67.
11. Defrance T, Vanbervliet B, Aubry JP, Takebe Y, Arai N, Miyajima A, Yokota T, Lee F, Arai KI, De Vries JE, Banchereau J. B-cell growth promoting activity of recombinant human interleukin 4. J Immunol 1987;139:1135-41.
12. Hoon DSB, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with 7-interferon or tumor necrosis factor. Cancer Res 1991;51:2002-8.
13. Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, Hood DSB. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res 1992;52: 6059-65.
14. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin 4. J Clin Invest 1993;91:88-93.
15. Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-9.
16. Topp MS, Papdimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995;55:2173-6.
17. Bosco M, Giovarelli M, Forni M, et al. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibited the growth of poorly and apparently nonimmunogenic tumors and induced a tumor-specific immune memory. J Immunol 1990; 145:3136-43.
18. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
19. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
20. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257:548-51.
21. Van der Brüggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
22. Carrel S, Rimoldi D. Melanoma-associated antigens. Eur J Cancer 1993;29A: 1903-7.
23. Saliusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor. J Exp Med 1994; 179: 1109-18.
24. Maggi E, Parronchi P, Manetti R, et al. Reciprocal regulatory effects of IFN-“y and IL-4 on the in vitro development of human Thl and Th2 clones. J Immunol 1992;148:2142-7.
25. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of the Th2-like helper effectors. J Immunol 1990; 145:3796-806.
26. Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Clin Cancer Res 1995;1:1145-52.